How should CUT-MIX dosing be structured across a 10-week competition prep cycle?

Dosing is typically highest in early prep (300–450mg/week) and tapered progressively toward peak week. This descending structure aligns anabolic stimulus with increasing caloric restriction, allowing the body to retain lean mass while achieving the conditioning depth required for competitive physique presentation. Weekly body composition checks guide dose adjustments.

When during contest prep should an athlete begin reducing their CUT-MIX dose?

Most experienced competitors begin a gradual dose reduction from week 7–8 onward, with the steepest taper occurring in the final 2 weeks. Cutting dose volume too early risks accelerated muscle breakdown under hypocaloric conditions; cutting too late leaves insufficient clearance time before stage day.

What weekly dose range is considered standard for advanced competitors using a 300mg/ml blend in pre-contest phases?

Advanced competitors typically work within a 300–600mg/week total blend range during pre-contest phases, though the optimal dose is individual and influenced by body weight, prior cycle history, and competitive division. Doses above 600mg/week for 300mg/ml blends are associated with proportionally greater side-effect burden and require more intensive monitoring.

Can the CUT-MIX 10ml vial be drawn with an insulin syringe for precise low-volume dosing?

At 300mg/ml, the minimum practical volume for an insulin syringe (1ml capacity) is 0.1ml = 30mg per draw. While insulin syringes can draw from a standard vial with an 18G transfer needle for filling, the 300mg/ml concentration means even half-ml draws deliver 150mg — making insulin-syringe micro-dosing feasible but requiring careful volumetric calculation to avoid accidental overdose.

How should the CUT-MIX vial be stored after opening, and does refrigeration affect oil solubility?

After the first puncture, store the vial at room temperature (15–25°C) away from direct light and heat sources; refrigeration is not required and may cause the oil carrier to thicken, making drawing more difficult. The chlorobutyl rubber stopper maintains a sterile barrier across the vial's multi-dose lifespan when punctured with a clean needle each time. Discard unused product 28 days after first use. (2) angle_used

Original Product

Master Pharma

CUT-MIX 300mg/ml 10ml Vial by Master Pharma

Name: CUT-MIX
Brand: Master Pharma
SKU: INJ-MIX-MAS-300-013
Price: 45.00 EUR
Availability: InStock

CUT-MIX by Master Pharma is a 300mg/ml injectable blend formulated specifically to support structured, competition-phase dosing protocols across the final weeks of a physique preparation cycle. The 10ml multi-dose vial delivers sufficient volume for a full contest-prep block without mid-cycle resupply interruptions. Quality is verified at the batch level: HPLC potency confirmation, LAL endotoxin testing, and GMP-compliant fill-finish underpin every released lot.

€45.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

300mg/ml concentration minimises injection volume per dose during calorie-restricted prep
10ml vial provides enough material to cover a full 10–12 week contest-prep block
Multi-dose format allows dose adjustments week-to-week as competition date nears
GMP-compliant production reduces batch-to-batch potency variability that could distort peak-week outcomes
HPLC-verified compound fractions ensure each draw reflects the declared concentration
LAL-tested for endotoxin compliance, reducing injection-site inflammatory interference during final prep
Master Pharma's lot-specific documentation supports traceable, repeatable competition-cycle planning

Phase	dosage	Note
Early Prep (Weeks 1–4)	300–450mg/week (1.0–1.5ml)	Establish baseline tissue response; monitor strength and body composition via caliper or DEXA
Mid Prep (Weeks 5–8)	300mg/week (1.0ml)	Maintain anabolic stimulus while progressive caloric reduction deepens; adjust if recovery quality declines
Peak Phase (Weeks 9–10)	150–300mg/week (0.5–1.0ml)	Taper toward competition date; water and electrolyte manipulation begins independently of dose
Final Week	Physician-guided; many athletes cease compounds 5–7 days pre-show	Ester half-life determines residual plasma levels; cessation timing is ester-specific

Key takeaways

Calibrate weekly dose against competition date and peak-week timeline.
Reduce injection frequency gradually as peak week approaches.
Track body composition bi-weekly to fine-tune dose response.
Confirm HPLC batch documentation before starting any contest cycle.
Plan PCT entry date based on ester clearance from final injection.

Competition-Phase Dosing: The Core Function of CUT-MIX

CUT-MIX by Master Pharma is a 300mg/ml injectable oil-solution engineered around the specific pharmacological demands of structured contest-preparation dosing, where precision, timing, and compound consistency directly influence competitive outcomes. Competition dosing differs fundamentally from off-season volume phases: the goal is not maximum anabolic output but controlled tissue preservation under progressive caloric restriction, timed to peak on a fixed date. CUT-MIX delivers the compound density required to achieve that control within a practical injection volume.

The blend supports a descending-dose model: higher weekly exposure in the early prep block (weeks 1–4) transitions to a maintenance range (weeks 5–8), with a final taper through peak week. Compared to lower-concentration 150mg/ml blends, CUT-MIX halves the injection volume at equivalent weekly doses — a meaningful advantage when athletes are already managing caloric restriction, dehydration protocols, and high-frequency training that reduces overall physical tolerance to large-volume intramuscular injections.

Pharmacological Anchors for Contest Timing

CUT-MIX contains an androgenic compound combination whose ester profiles govern two critical contest-prep variables: plasma stability across the prep timeline and PCT initiation timing post-competition. Stable plasma levels — maintained through an appropriate injection frequency matched to the active esters — prevent the trough-induced catabolism that erodes conditioning in the final weeks before competition. HPLC analysis of each Master Pharma batch confirms per-compound potency against the 300mg/ml label declaration, providing athletes with a reliable pharmacokinetic baseline for dose calculations.

The 10ml vial format covers a full 10–12 week prep block at standard weekly doses without resupply gaps — a practical requirement in structured contest prep where mid-cycle product changes introduce unnecessary variables.

Monitoring and Output Verification During Prep

Master Pharma subjects every CUT-MIX production lot to LAL endotoxin testing to injectable-grade acceptance criteria, reducing the risk of injection-site inflammatory responses that could mask legitimate conditioning progress through localised fluid retention. Athletes using CUT-MIX in competition prep should conduct bi-weekly caliper or DEXA-based body composition assessments to verify that dose, diet, and training are producing expected conditioning trajectories. Blood panel monitoring — including lipids, haematocrit (target below 52%), and liver enzymes — should occur at cycle start and at week 4.

Usage

Confirm competition date at least 10–12 weeks in advance and back-calculate your dosing calendar from peak week to cycle start.
Inspect the 10ml vial for particulate matter and verify the lot number against the HPLC certificate before drawing the first dose.
Using an 18–21G draw needle, aspirate the required volume (1.0ml = 300mg at label concentration); switch to a 23–25G injection needle for administration.
Rotate injection sites across bilateral glutes and lateral quads on a structured schedule — shorter esters in this blend favour every-other-day or twice-weekly administration to sustain stable plasma levels during prep.
Log each injection (site, volume, date) alongside weekly body weight and caliper measurements to correlate dose response with conditioning progress as the competition date approaches.
Plan PCT initiation based on the shortest active ester's clearance window — typically 3–5 days post-final-injection for propionate-class esters — and have SERM agents confirmed and in hand before the contest cycle begins.

Warnings

contraindications: Not indicated for individuals with androgen-sensitive conditions, active cardiovascular disease, hepatic impairment, or elevated haematocrit above 50%. Women and individuals under 21 years of age should not use this product. Not for use during pregnancy or lactation.

side_effects: Androgenic effects including acne, accelerated hair thinning, and virilisation in female users. Potential for HPG axis suppression, libido fluctuation, and mood variability during calorie-restricted contest prep. Elevated LDL / reduced HDL lipid profile changes are reported with androgenic compounds.

monitoring: Complete blood count, lipid panel, and blood pressure checks at baseline and at weeks 4 and 8 of cycle. Haematocrit should remain below 52% (WADA/sports-medicine threshold). Liver enzyme screening (ALT/AST) is recommended even with injectable-only protocols.

pct: Post-cycle therapy with a SERM (e.g. tamoxifen or clomiphene) should begin according to the clearance window of the active esters present. Confirm ester half-lives with your prescribing physician. Hormonal restoration typically requires 4–6 weeks of structured PCT following competition-phase cycling.

Frequently asked questions

How should CUT-MIX dosing be structured across a 10-week competition prep cycle?: Dosing is typically highest in early prep (300–450mg/week) and tapered progressively toward peak week. This descending structure aligns anabolic stimulus with increasing caloric restriction, allowing the body to retain lean mass while achieving the conditioning depth required for competitive physique presentation. Weekly body composition checks guide dose adjustments.
When during contest prep should an athlete begin reducing their CUT-MIX dose?: Most experienced competitors begin a gradual dose reduction from week 7–8 onward, with the steepest taper occurring in the final 2 weeks. Cutting dose volume too early risks accelerated muscle breakdown under hypocaloric conditions; cutting too late leaves insufficient clearance time before stage day.
What weekly dose range is considered standard for advanced competitors using a 300mg/ml blend in pre-contest phases?: Advanced competitors typically work within a 300–600mg/week total blend range during pre-contest phases, though the optimal dose is individual and influenced by body weight, prior cycle history, and competitive division. Doses above 600mg/week for 300mg/ml blends are associated with proportionally greater side-effect burden and require more intensive monitoring.
Can the CUT-MIX 10ml vial be drawn with an insulin syringe for precise low-volume dosing?: At 300mg/ml, the minimum practical volume for an insulin syringe (1ml capacity) is 0.1ml = 30mg per draw. While insulin syringes can draw from a standard vial with an 18G transfer needle for filling, the 300mg/ml concentration means even half-ml draws deliver 150mg — making insulin-syringe micro-dosing feasible but requiring careful volumetric calculation to avoid accidental overdose.
How should the CUT-MIX vial be stored after opening, and does refrigeration affect oil solubility?: After the first puncture, store the vial at room temperature (15–25°C) away from direct light and heat sources; refrigeration is not required and may cause the oil carrier to thicken, making drawing more difficult. The chlorobutyl rubber stopper maintains a sterile barrier across the vial's multi-dose lifespan when punctured with a clean needle each time. Discard unused product 28 days after first use. (2) angle_used

Manufacturer

Authenticity verification is the operational centrepiece of Master Pharma's product release system for CUT-MIX — and that verification is consumer-accessible, not internal-only. Each 10ml vial carries a holographic security label printed with a unique alphanumeric code; scanning or manually entering that code on Master Pharma's verification portal returns the corresponding batch record, including production date and HPLC potency result for that specific lot. The hologram substrate is designed to void irreversibly on attempted removal, preventing label transfer between vials. Batch traceability extends to the fill-finish stage: every lot of CUT-MIX is documented under GMP process controls, with LAL endotoxin testing confirming compliance to parenteral acceptance limits before release. For competition-phase athletes where product authenticity directly affects preparation outcomes, this code-level verification architecture provides a concrete, checkable quality reference rather than a brand-level claim.

Product details

Brand	Master Pharma
Active ingredient	mix product
Also known as	Steroid-Mix, Mehrkomponenten-Mischung, Cut Mix, CUT-MIX, Master Pharma Steroid-Mix
Strength	300 mg
Form	Vial
Pack size	1 piece
Item number	INJ-MIX-MAS-300-013

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Mixobolin-200 200mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Hardcore Cutting

Mixobolin-200 200mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Mixobolin-200 by BM Pharmaceuticals combines Trenbolone Acetate 50mg, Drostanolone Propionate 50mg, and Testosterone Propionate 100mg per millilitre — 200mg/ml total — across 10 individually sealed single-dose glass ampoules, formulated to distribute androgen receptor occupancy across three mechanistically distinct compound classes rather than concentrating binding pressure through a single high-affinity pathway. All three propionate and acetate esters clear within 2–3 days, allowing cycle termination to be executed precisely when training output signals diminishing receptor responsiveness, with post-cycle therapy starting as early as 3–5 days after the final ampoule. Per-compound HPLC quantification and LAL endotoxin screening are applied at batch level; each ampoule is hermetically sealed under nitrogen-blanketed aseptic fill conditions before carton assembly.

€76.00

Recomp Optimizer

Mix Products Injection 250mg/ml 10ml Vial by Genesis

Genesis Mix Products Injection is a 250mg/ml tri-ester hybrid injectable combining Trenbolone Acetate 40mg, Nandrolone Decanoate 90mg, and Testosterone Mix 120mg per ml, formulated specifically to support precise microdosing protocols in a 10ml multi-dose vial. The dual 19-nor structure combined with a testosterone base makes post-cycle therapy exceptionally demanding — users must expect an aggressive, extended SERM regimen beginning approximately 14–21 days after the final injection, timed to the decanoate ester's clearance. Vial integrity, concentration accuracy, and sterility are verified through reversed-phase HPLC quantification and LAL endotoxin testing; every released batch carries a traceable certificate of analysis.

€54.00

Mass Building

NTD 400 400mg/ml 10ml Vial by GenTec

GenTec NTD 400 is a 400mg/ml tri-ester injectable blend — Nandrolone Decanoate 100mg, Drostanolone Enanthate 100mg, Testosterone Enanthate 200mg — formulated specifically for cruise & blast mass-building protocols in a 10ml multi-dose vial. Each millilitre delivers 4,000mg of total active ingredient across the full vial, with long-acting esters sustaining stable plasma levels throughout extended blast phases without the need for daily injections. Quality assurance is enforced through HPLC concentration verification, LAL endotoxin testing, and GMP-compliant aseptic fill-and-finish; batch certificates are available per lot.

€50.00

Best Value

Cut Stack 150 150mg/ml 10ml Vial by Hilma Biocare

Cut Stack 150 by Hilma Biocare is a 150mg/ml injectable cutting blend — Testosterone Propionate 50mg/ml, Trenbolone Acetate 50mg/ml, and Drostanolone Propionate 50mg/ml — supplied in a 10ml multi-dose vial and formulated exclusively for advanced cutting protocols, with an absolute contraindication against TRT or anti-aging use. Because all three compounds carry a 2–3 day half-life, plasma levels fall to sub-suppressive thresholds within days of the final injection, opening the post-cycle recovery window approximately 3–5 days after the last dose — a materially earlier point than long-ester injectable cycles, and driven by ester hydrolysis rather than the hepatic clearance kinetics that govern oral-cycle PCT scheduling. Every production lot is released under Hilma Biocare's analytical framework: HPLC potency confirmation and LAL endotoxin testing applied batch-by-batch, with certificates accessible via the brand's verification portal.

€54.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00